Latest News & Features
Americas
A procedural change at the Patent Trial and Appeal Board offers petitioners a valuable tool to push back against Fintiv-based discretionary denial, writes Taylor Stemler of Merchant & Gould. 14 August 2025
Americas
A patent fee structure being mooted in the US could hurt the innovation economy, especially in industries like biotech and pharma—and will face backlash from businesses, writes Paul Hunter of Foley. 12 August 2025
Africa
Africa’s agricultural future is imperative to life and prosperity in the region—and the Arusha Protocol gives breeders the protection they need, explains the African Regional Intellectual Property Organization. 15 July 2025
Europe
Despite efforts to harmonise, the Unified Patent Court’s local divisions and Court of Appeal have signalled a divergence over implementing the European Patent Convention—but does it matter? Chris Moore and Hsu Min Chung of HGF report. 19 June 2025
Europe
Two years since the UPC opened its doors, various developments might influence the UK government to reassess its position, write Amanda Ebbutt and Paul England of Taylor Wessing. 10 June 2025
Europe
A new law affecting disputes concerning the ‘Bolar provision’ could allow competitors to enter the Ukrainian market before a patent expires, explains Volodymyr Hrunskyi of Sayenko Kharenko. 3 June 2025
Africa
Genomic innovations involve vast amounts of research, making patents, copyrights, and trade secrets vital, explains Olusola Tunmise-Ajani of Inventa International. 29 April 2025
Europe
Following the Unified Patent Court’s recent Meril v Edwards decision, Agathe Michel-de Cazotte & Ben Chapman of Carpmaels & Ransford examine the court’s treatment of obviousness to date. 24 April 2025
Europe
For those willing to undertake the complexity, in vivo cell therapy could redefine the economics and logistics of cell-based treatment, says Adam Gregory of Mewburn Ellis. 22 April 2025
Europe
Supplementary Protection Certificate rules interpreted in different ways have left the EU’s generic and biosimilar industries hungry for clarity, explains Jiri Slavik of Adalvo. 25 March 2025